MA29321B1 - Vaccin a base de rotavirus vivant attenue pour administration orale - Google Patents

Vaccin a base de rotavirus vivant attenue pour administration orale

Info

Publication number
MA29321B1
MA29321B1 MA30201A MA30201A MA29321B1 MA 29321 B1 MA29321 B1 MA 29321B1 MA 30201 A MA30201 A MA 30201A MA 30201 A MA30201 A MA 30201A MA 29321 B1 MA29321 B1 MA 29321B1
Authority
MA
Morocco
Prior art keywords
oral administration
rotavirus
live attenuated
rotavirus vaccine
attenuated rotavirus
Prior art date
Application number
MA30201A
Other languages
English (en)
Inventor
Velde Vincent Vande
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34385675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29321(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29321B1 publication Critical patent/MA29321B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES FORMULATIONS LIQUIDES DE ROTAVIRUS QUI CONVIENNENT POUR UNE ADMINISTRATION ORALE AUX NOURRISSONS HUMAINS. EN PARTICULIER, L¿INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES ET DES VACCINS COMPRENANT UN ANTIGÈNE DE ROTAVIRUS, UN SUCRE ET UN CARBOXYLATE, LEUR FORMULATION AYANT UN PH COMPRIS ENTRE PH 5.0 ET PH 8.0 ET NE COMPRENANT PAS DE PHOSPHATE OU MOINS DE 5 MM DE PHOSPHATE. CETTE INVENTION DÉCRIT ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DESDITES FORMULATIONS DE ROTAVIRUS ET L¿UTILISATION DE CELLES-CI DANS LA PRÉVENTION OU LE TRAITEMENT DES MALADIES ASSOCIÉES AU ROTAVIRUS CHEZ LES HUMAINS.
MA30201A 2005-02-17 2007-09-10 Vaccin a base de rotavirus vivant attenue pour administration orale MA29321B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0503337.8A GB0503337D0 (en) 2005-02-17 2005-02-17 Compositions

Publications (1)

Publication Number Publication Date
MA29321B1 true MA29321B1 (fr) 2008-03-03

Family

ID=34385675

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30201A MA29321B1 (fr) 2005-02-17 2007-09-10 Vaccin a base de rotavirus vivant attenue pour administration orale

Country Status (32)

Country Link
US (2) US8192747B2 (fr)
EP (2) EP1863526B1 (fr)
JP (1) JP5118977B2 (fr)
KR (1) KR101319846B1 (fr)
CN (2) CN101300028B (fr)
AP (1) AP2692A (fr)
AR (1) AR053680A1 (fr)
AT (1) ATE516044T1 (fr)
AU (1) AU2006215761B2 (fr)
BR (1) BRPI0608877B8 (fr)
CA (1) CA2598290C (fr)
CY (1) CY1111916T1 (fr)
DK (1) DK1863526T3 (fr)
EA (1) EA012046B1 (fr)
ES (1) ES2369246T3 (fr)
GB (1) GB0503337D0 (fr)
HR (1) HRP20110668T1 (fr)
IL (1) IL184802A0 (fr)
MA (1) MA29321B1 (fr)
MX (1) MX2007010075A (fr)
MY (1) MY145790A (fr)
NO (1) NO341789B1 (fr)
NZ (1) NZ560314A (fr)
PE (1) PE20061094A1 (fr)
PL (1) PL1863526T3 (fr)
PT (1) PT1863526E (fr)
SI (1) SI1863526T1 (fr)
TW (1) TWI358303B (fr)
UA (1) UA91044C2 (fr)
UY (1) UY29377A1 (fr)
WO (1) WO2006087205A1 (fr)
ZA (1) ZA200706668B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008014391A (es) * 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
EP2197283B1 (fr) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations pour la préservation de rotavirus
EP2236617A1 (fr) 2009-03-31 2010-10-06 Leukocare Ag Procédés de stérilisation de terminal de compositions biofonctionnelles
CA3121654A1 (fr) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nouvelles souches de rotavirus humain et nouveaux vaccins
CN101972475B (zh) * 2010-04-12 2014-04-09 李建平 一种细菌多糖-蛋白结合疫苗及其制备方法
CN101863966B (zh) * 2010-05-21 2012-10-03 中国人民解放军第三军医大学 抗轮状病毒药物作用靶标及其构建方法和应用方法
EA030970B8 (ru) 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
EP2471554A1 (fr) 2010-12-28 2012-07-04 Hexal AG Formulation pharmaceutique comprenant un médicament biopharmaceutique
WO2012103464A2 (fr) * 2011-01-28 2012-08-02 Brian Pulliam Préparation de vaccin sous forme de mince film oral
CN103747800A (zh) * 2011-04-28 2014-04-23 国际医学基金会 液体疫苗制剂
CN102349932B (zh) * 2011-10-12 2012-12-26 刘壮华 一种治疗息肉的药物制剂
WO2013105105A2 (fr) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Nouvelles compositions de vaccins viraux et méthodes de préparation de tels vaccins
EA034014B1 (ru) * 2012-02-08 2019-12-19 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Способ лечения субъекта с диареей, вызванной ротавирусом
BR112014020930A2 (pt) 2012-03-05 2017-06-27 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
BR112014026407B1 (pt) * 2012-04-23 2020-12-22 Bharat Biotech International Limited formulação de vacina líquida
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP4417256A3 (fr) 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Matériaux et procédés pour améliorer la fonction pulmonaire
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
CN103316336B (zh) * 2013-05-31 2015-01-28 北京科兴中维生物技术有限公司 一种适于口服的轮状病毒疫苗
CN103316335B (zh) * 2013-05-31 2014-11-12 北京科兴生物制品有限公司 一种适于口服的脊髓灰质炎病毒疫苗
EP3021833B2 (fr) * 2013-07-19 2022-03-30 Hexal Aktiengesellschaft Procédés et formulations qui permettent à la modulation de réponses immunitaires associées à l'administration d'un médicament biopharmaceutique
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP3053594A4 (fr) * 2013-10-03 2017-05-10 Nitto Denko Corporation Préparation de vaccin antigrippal séchée, et procédé pour produire une préparation de vaccin antigrippal séchée
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN104524562A (zh) * 2014-12-08 2015-04-22 武汉生物制品研究所有限责任公司 口服六价重配轮状病毒活疫苗
WO2017062246A1 (fr) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Souche de rotavirus humain g9p[6] et utilisation comme vaccin
EP3389786A4 (fr) * 2015-12-18 2019-08-21 Merck Sharp & Dohme Corp. Formulations thermiquement stables de vaccin anti-rotavirus et leurs méthodes d'utilisation
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
AU2019254473A1 (en) * 2018-04-16 2020-12-03 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
CN110946871A (zh) * 2019-12-12 2020-04-03 浙江华康药业股份有限公司 槐糖在制备预防和治疗肥胖产品中的应用及对应产品
CN115531364B (zh) * 2021-06-30 2024-02-23 中国科学技术大学 预防或治疗轮状病毒感染的微生物代谢物制剂及其用途
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
JP2849632B2 (ja) 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2121841T3 (es) 1990-11-16 1998-12-16 Childrens Hosp Medical Center Una vacuna para proporcionar proteccion inmunologica contra enfermedades de rotavirus en humanos.
NZ240818A (en) * 1990-12-14 1993-08-26 Mcneil Ppc Inc Liquid sucralose concentrate compositions containing preservative, buffer and liquid
HUT67006A (en) * 1991-08-05 1995-01-30 Sterling Winthrop Inc Buffered composition containing mammalian superoxide-dismutase/polyethylene glycol coniugate
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2138997C (fr) 1992-06-25 2003-06-03 Jean-Paul Prieels Composition vaccinale qui contient des adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
JP3967769B2 (ja) 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
EP1891968A3 (fr) 1996-09-26 2008-09-03 Merck & Co., Inc. Formulations de vaccins à rotavirus
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
WO1998056415A1 (fr) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Saponines purifiees servant d'adjuvants oraux
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
US7157092B1 (en) 1998-06-30 2007-01-02 Om Pharma Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
SK287261B6 (sk) * 1999-08-17 2010-04-07 Smithkline Beecham Biologicals S.A. Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
CA2398428C (fr) 2000-01-28 2015-09-08 Albert Kapikian Compositions et procede pour prevenir la reactogenicite associee a l'administration de compositions de rotavirus vivants immunogenes

Also Published As

Publication number Publication date
EP1863526B1 (fr) 2011-07-13
CY1111916T1 (el) 2015-11-04
NZ560314A (en) 2011-02-25
GB0503337D0 (en) 2005-03-23
CN103357005A (zh) 2013-10-23
UA91044C2 (uk) 2010-06-25
MY145790A (en) 2012-04-30
ZA200706668B (en) 2009-07-29
US20080166372A1 (en) 2008-07-10
TW200640486A (en) 2006-12-01
US8192747B2 (en) 2012-06-05
JP5118977B2 (ja) 2013-01-16
AR053680A1 (es) 2007-05-16
UY29377A1 (es) 2006-10-02
BRPI0608877B1 (pt) 2021-02-09
NO20073868L (no) 2007-11-15
US8821891B2 (en) 2014-09-02
SI1863526T1 (sl) 2011-11-30
KR101319846B1 (ko) 2013-10-22
AP2007004087A0 (en) 2007-08-31
PE20061094A1 (es) 2006-11-30
ATE516044T1 (de) 2011-07-15
NO341789B1 (no) 2018-01-22
PL1863526T3 (pl) 2011-12-30
US20120237547A1 (en) 2012-09-20
CN101300028A (zh) 2008-11-05
WO2006087205A1 (fr) 2006-08-24
JP2008530165A (ja) 2008-08-07
TWI358303B (en) 2012-02-21
CA2598290C (fr) 2015-08-11
EA200701519A1 (ru) 2008-02-28
EP1863526A1 (fr) 2007-12-12
ES2369246T3 (es) 2011-11-28
AU2006215761A1 (en) 2006-08-24
AP2692A (en) 2013-07-16
EP2322211A1 (fr) 2011-05-18
AU2006215761B2 (en) 2011-03-17
IL184802A0 (en) 2007-12-03
CN101300028B (zh) 2014-06-04
PT1863526E (pt) 2011-10-11
BRPI0608877B8 (pt) 2021-05-25
BRPI0608877A2 (pt) 2012-07-31
DK1863526T3 (da) 2011-10-24
HRP20110668T1 (hr) 2011-10-31
KR20070103506A (ko) 2007-10-23
MX2007010075A (es) 2008-01-16
CA2598290A1 (fr) 2006-08-24
EA012046B1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
MY145790A (en) Composition
EP1790340A3 (fr) Chimotherapie combinée
EP1478371A4 (fr) Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
MA29715B1 (fr) Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b
NL300728I1 (fr)
MA29681B1 (fr) Formes galeniques du risedronate
WO2003061578A3 (fr) Compositions destinees a traiter ou prevenir les effets d'une attaque bioterroriste
Nason et al. Lipopolysaccharide-induced osteoclastogenesis from mononuclear precursors: a mechanism for osteolysis in chronic otitis
World Health Organization Yellow fever fact sheet:(revised in December 2009)= Aide-mémoire sur la fièvre jaune:(révisé en décembre 2009)
TW200600121A (en) Pharmaceutical dosage forms
ES2356371T3 (es) Medicamentos terapéuticos para inducir tolerancia.
EP4062931A1 (fr) Nouvelle application d'une composition immunogene ou vaccinale
Ahmed et al. The Salivary Secretion and Biochemical Composition Analysis in Patients with Helicobacter pyloriInfection
Ju et al. Alternative therapies with tacrolimus and low-dose doxycycline for oral chronic graft-versus-host disease that is resistant to topical corticosteroid medication: case report
EP4313142A1 (fr) Nouvelle application d'une composition immunogene ou vaccinale
TH83579B (th) สารผสม
Jernigan Lyme Toxins: The Primary Cause of Your Symptoms!